GCM
KZR

Graham Capital Management’s Kezar Life Sciences KZR Stock Holding History

Graham Capital Management’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-38,605
Closed -$3.32M – 1185
2022
Q3 		$3.32M Buy
38,605
+1,551
+4% +$151K 0.13% 105
2022
Q2 		$3.06M Buy
37,054
+32,492
+712% +$2.87M 0.12% 110
2022
Q1 		$758K Buy
4,562
+3,326
+269% +$477K 0.03% 405
2021
Q4 		$206K Buy
+1,236
New +$140K 0.01% 463

Other funds holding KZR

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Graham Capital Management's KZR Position: Q4 2022 in Review

Graham Capital Management sold out of Kezar Life Sciences (KZR) in Q4 2022, closing a stake of 38,605 shares — an estimated $3.32M sold.

Graham Capital Management first reported a position in KZR in Q4 2021 and held it in 4 quarters. The position peaked at $3.32M in Q3 2022. 123 funds tracked by Wall St. Rank hold KZR as of Q4 2022.

  • Graham Capital Management reported no remaining Kezar Life Sciences position as of Q4 2022 after selling out during the quarter.
  • Graham Capital Management sold 38,605 Kezar Life Sciences shares in Q4 2022, an estimated $3.32M.
  • Graham Capital Management first reported a position in Kezar Life Sciences in Q4 2021 and held it in 4 quarters.
  • Graham Capital Management's Kezar Life Sciences position peaked at $3.32M in Q3 2022.
  • 123 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q4 2022.

Based on Graham Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.